Summary

Global Beta Lactam And Beta Lactamase Inhibitors Market 2024-2028
The beta lactam and beta lactamase inhibitors market is forecasted to grow by USD 10.06 bn during 2023-2028, accelerating at a CAGR of 5.47% during the forecast period. The report on the beta lactam and beta lactamase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising focus on novel drug development, rising antimicrobial resistance, and high disease burden in developing countries.
Technavio's beta lactam and beta lactamase inhibitors market is segmented as below:
By Route Of Administration
• Oral
• Intravenous
• Others
By Drug Class
• Cephalosporins
• Penicillins
• Carbapenems
• Monobactams
• Combination
By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the technological advancements in antibiotic discovery as one of the prime reasons driving the beta lactam and beta lactamase inhibitors market growth during the next few years. Also, increased emphasis on antibiotic stewardship and growing emphasis on HAIS will lead to sizable demand in the market.
The report on the beta lactam and beta lactamase inhibitors market covers the following areas:
• Beta lactam and beta lactamase inhibitors market sizing
• Beta lactam and beta lactamase inhibitors market forecast
• Beta lactam and beta lactamase inhibitors market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading beta lactam and beta lactamase inhibitors market vendors that include AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Ltd., GlaxoSmithKline Plc, Jaiwik Biotech, Lupin Ltd., MedPlus Health Services Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Numera Life Sciences, Pfizer Inc., Sandoz AG, Sanofi SA, Spero Therapeutics, Taj Pharmaceutical Ltd., Zeelab Laboratories Ltd., Abbott Laboratories, and F. Hoffmann La Roche Ltd.. Also, the beta lactam and beta lactamase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/beta-lactam-and-beta-lactamase-inhibitors-market-industry-analysis
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

ページTOPに戻る

Table of Contents

- 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Global Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
- 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
- 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
o Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
- 4 Historic Market Size
o 4.1 Global beta lactam and beta lactamase inhibitors market 2018 - 2022
o Exhibit 18: Historic Market Size - Data Table on global beta lactam and beta lactamase inhibitors market 2018 - 2022 ($ billion)
o 4.2 Route of Administration Segment Analysis 2018 - 2022
o Exhibit 19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ billion)
o 4.3 Drug Class Segment Analysis 2018 - 2022
o Exhibit 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ billion)
o 4.4 Geography Segment Analysis 2018 - 2022
o Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
o 4.5 Country Segment Analysis 2018 - 2022
o Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
- 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
- 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
o Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Oral - Market size and forecast 2023-2028
o Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
o Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
o Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
o 6.4 Intravenous - Market size and forecast 2023-2028
o Exhibit 38: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion)
o Exhibit 39: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion)
o Exhibit 40: Chart on Intravenous - Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Intravenous - Year-over-year growth 2023-2028 (%)
o 6.5 Others - Market size and forecast 2023-2028
o Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ billion)
o Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
o Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
o Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
o 6.6 Market opportunity by Route of Administration
o Exhibit 46: Market opportunity by Route of Administration ($ billion)
o Exhibit 47: Data Table on Market opportunity by Route of Administration ($ billion)
- 7 Market Segmentation by Drug Class
o 7.1 Market segments
o Exhibit 48: Chart on Drug Class - Market share 2023-2028 (%)
o Exhibit 49: Data Table on Drug Class - Market share 2023-2028 (%)
o 7.2 Comparison by Drug Class
o Exhibit 50: Chart on Comparison by Drug Class
o Exhibit 51: Data Table on Comparison by Drug Class
o 7.3 Cephalosporins - Market size and forecast 2023-2028
o Exhibit 52: Chart on Cephalosporins - Market size and forecast 2023-2028 ($ billion)
o Exhibit 53: Data Table on Cephalosporins - Market size and forecast 2023-2028 ($ billion)
o Exhibit 54: Chart on Cephalosporins - Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Cephalosporins - Year-over-year growth 2023-2028 (%)
o 7.4 Penicillins - Market size and forecast 2023-2028
o Exhibit 56: Chart on Penicillins - Market size and forecast 2023-2028 ($ billion)
o Exhibit 57: Data Table on Penicillins - Market size and forecast 2023-2028 ($ billion)
o Exhibit 58: Chart on Penicillins - Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Penicillins - Year-over-year growth 2023-2028 (%)
o 7.5 Carbapenems - Market size and forecast 2023-2028
o Exhibit 60: Chart on Carbapenems - Market size and forecast 2023-2028 ($ billion)
o Exhibit 61: Data Table on Carbapenems - Market size and forecast 2023-2028 ($ billion)
o Exhibit 62: Chart on Carbapenems - Year-over-year growth 2023-2028 (%)
o Exhibit 63: Data Table on Carbapenems - Year-over-year growth 2023-2028 (%)
o 7.6 Monobactams - Market size and forecast 2023-2028
o Exhibit 64: Chart on Monobactams - Market size and forecast 2023-2028 ($ billion)
o Exhibit 65: Data Table on Monobactams - Market size and forecast 2023-2028 ($ billion)
o Exhibit 66: Chart on Monobactams - Year-over-year growth 2023-2028 (%)
o Exhibit 67: Data Table on Monobactams - Year-over-year growth 2023-2028 (%)
o 7.7 Combination - Market size and forecast 2023-2028
o Exhibit 68: Chart on Combination - Market size and forecast 2023-2028 ($ billion)
o Exhibit 69: Data Table on Combination - Market size and forecast 2023-2028 ($ billion)
o Exhibit 70: Chart on Combination - Year-over-year growth 2023-2028 (%)
o Exhibit 71: Data Table on Combination - Year-over-year growth 2023-2028 (%)
o 7.8 Market opportunity by Drug Class
o Exhibit 72: Market opportunity by Drug Class ($ billion)
o Exhibit 73: Data Table on Market opportunity by Drug Class ($ billion)
- 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 75: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 76: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 77: Chart on Geographic comparison
o Exhibit 78: Data Table on Geographic comparison
o 9.3 North America - Market size and forecast 2023-2028
o Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
o Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
o Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
o 9.4 Europe - Market size and forecast 2023-2028
o Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
o Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
o Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
o 9.5 Asia - Market size and forecast 2023-2028
o Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
o Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
o Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
o Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
o Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
o Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o 9.7 US - Market size and forecast 2023-2028
o Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
o Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
o Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)
o 9.8 China - Market size and forecast 2023-2028
o Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
o Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
o Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
o 9.9 Germany - Market size and forecast 2023-2028
o Exhibit 103: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
o Exhibit 104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
o Exhibit 105: Chart on Germany - Year-over-year growth 2023-2028 (%)
o Exhibit 106: Data Table on Germany - Year-over-year growth 2023-2028 (%)
o 9.10 India - Market size and forecast 2023-2028
o Exhibit 107: Chart on India - Market size and forecast 2023-2028 ($ billion)
o Exhibit 108: Data Table on India - Market size and forecast 2023-2028 ($ billion)
o Exhibit 109: Chart on India - Year-over-year growth 2023-2028 (%)
o Exhibit 110: Data Table on India - Year-over-year growth 2023-2028 (%)
o 9.11 UK - Market size and forecast 2023-2028
o Exhibit 111: Chart on UK - Market size and forecast 2023-2028 ($ billion)
o Exhibit 112: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
o Exhibit 113: Chart on UK - Year-over-year growth 2023-2028 (%)
o Exhibit 114: Data Table on UK - Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 115: Market opportunity By Geographical Landscape ($ billion)
o Exhibit 116: Data Tables on Market opportunity By Geographical Landscape ($ billion)
- 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 117: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
- 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 119: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 120: Impact of key risks on business
- 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 121: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 122: Matrix on vendor position and classification
o 12.3 Abbott Laboratories
o Exhibit 123: Abbott Laboratories - Overview
o Exhibit 124: Abbott Laboratories - Business segments
o Exhibit 125: Abbott Laboratories - Key offerings
o Exhibit 126: Abbott Laboratories - Segment focus
o 12.4 AbbVie Inc.
o Exhibit 127: AbbVie Inc. - Overview
o Exhibit 128: AbbVie Inc. - Product / Service
o Exhibit 129: AbbVie Inc. - Key news
o Exhibit 130: AbbVie Inc. - Key offerings
o 12.5 Alkem Laboratories Ltd.
o Exhibit 131: Alkem Laboratories Ltd. - Overview
o Exhibit 132: Alkem Laboratories Ltd. - Business segments
o Exhibit 133: Alkem Laboratories Ltd. - Key news
o Exhibit 134: Alkem Laboratories Ltd. - Key offerings
o Exhibit 135: Alkem Laboratories Ltd. - Segment focus
o 12.6 Astellas Pharma Inc.
o Exhibit 136: Astellas Pharma Inc. - Overview
o Exhibit 137: Astellas Pharma Inc. - Product / Service
o Exhibit 138: Astellas Pharma Inc. - Key news
o Exhibit 139: Astellas Pharma Inc. - Key offerings
o 12.7 Cipla Ltd.
o Exhibit 140: Cipla Ltd. - Overview
o Exhibit 141: Cipla Ltd. - Business segments
o Exhibit 142: Cipla Ltd. - Key news
o Exhibit 143: Cipla Ltd. - Key offerings
o Exhibit 144: Cipla Ltd. - Segment focus
o 12.8 F. Hoffmann La Roche Ltd.
o Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
o Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
o Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
o Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
o Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus
o 12.9 GlaxoSmithKline Plc
o Exhibit 150: GlaxoSmithKline Plc - Overview
o Exhibit 151: GlaxoSmithKline Plc - Business segments
o Exhibit 152: GlaxoSmithKline Plc - Key news
o Exhibit 153: GlaxoSmithKline Plc - Key offerings
o Exhibit 154: GlaxoSmithKline Plc - Segment focus
o 12.10 MedPlus Health Services Ltd.
o Exhibit 155: MedPlus Health Services Ltd. - Overview
o Exhibit 156: MedPlus Health Services Ltd. - Product / Service
o Exhibit 157: MedPlus Health Services Ltd. - Key offerings
o 12.11 Meiji Holdings Co. Ltd.
o Exhibit 158: Meiji Holdings Co. Ltd. - Overview
o Exhibit 159: Meiji Holdings Co. Ltd. - Business segments
o Exhibit 160: Meiji Holdings Co. Ltd. - Key news
o Exhibit 161: Meiji Holdings Co. Ltd. - Key offerings
o Exhibit 162: Meiji Holdings Co. Ltd. - Segment focus
o 12.12 Merck KGaA
o Exhibit 163: Merck KGaA - Overview
o Exhibit 164: Merck KGaA - Business segments
o Exhibit 165: Merck KGaA - Key news
o Exhibit 166: Merck KGaA - Key offerings
o Exhibit 167: Merck KGaA - Segment focus
o 12.13 Novartis AG
o Exhibit 168: Novartis AG - Overview
o Exhibit 169: Novartis AG - Business segments
o Exhibit 170: Novartis AG - Key news
o Exhibit 171: Novartis AG - Key offerings
o Exhibit 172: Novartis AG - Segment focus
o 12.14 Pfizer Inc.
o Exhibit 173: Pfizer Inc. - Overview
o Exhibit 174: Pfizer Inc. - Product / Service
o Exhibit 175: Pfizer Inc. - Key news
o Exhibit 176: Pfizer Inc. - Key offerings
o 12.15 Sandoz AG
o Exhibit 177: Sandoz AG - Overview
o Exhibit 178: Sandoz AG - Product / Service
o Exhibit 179: Sandoz AG - Key news
o Exhibit 180: Sandoz AG - Key offerings
o 12.16 Sanofi SA
o Exhibit 181: Sanofi SA - Overview
o Exhibit 182: Sanofi SA - Business segments
o Exhibit 183: Sanofi SA - Key news
o Exhibit 184: Sanofi SA - Key offerings
o Exhibit 185: Sanofi SA - Segment focus
o 12.17 Spero Therapeutics
o Exhibit 186: Spero Therapeutics - Overview
o Exhibit 187: Spero Therapeutics - Product / Service
o Exhibit 188: Spero Therapeutics - Key offerings
- 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 189: Inclusions checklist
o Exhibit 190: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 191: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 192: Research methodology
o Exhibit 193: Validation techniques employed for market sizing
o Exhibit 194: Information sources
o 13.5 List of abbreviations
o Exhibit 195: List of abbreviations